REGENXBIO keeps RGX-202 BLA submission on track for Q3 2026

Second-quarter update also said the company received more than $200 million in July 2026, lifting pro forma cash to about $313 million and setting up wet AMD data in Q4 2026.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.